Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study (Q84698071)

From Wikidata

Jump to navigation Jump to search

scientific article published on 06 August 2010

Language	Label	Description	Also known as
English	Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study	scientific article published on 06 August 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20693429%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20693429%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Hisashi Sakamaki

19

object named as

Hisashi Sakamaki

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20693429%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Chiaki Nakaseko

9

object named as

Chiaki Nakaseko

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20693429%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

6

object named as

Noriko Usui

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20693429%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

Shigeki Ohtake

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20693429%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Shuichi Miyawaki

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20693429%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Hiroyuki Fujita

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20693429%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Hitoshi Kiyoi

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20693429%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Katsuji Shinagawa

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20693429%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Hirokazu Okumura

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20693429%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Koichi Miyamura

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20693429%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Yasushi Miyazaki

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20693429%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Atsushi Fujieda

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20693429%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Tadashi Nagai

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20693429%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Takahisa Yamane

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20693429%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Masafumi Taniwaki

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20693429%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Masatomo Takahashi

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20693429%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Fumiharu Yagasaki

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20693429%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Yukihiko Kimura

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20693429%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Norio Asou

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20693429%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Hiroshi Handa

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20693429%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Sumihisa Honda

21

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20693429%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Kazunori Ohnishi

22

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20693429%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Tomoki Naoe

23

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20693429%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Ryuzo Ohno

24

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20693429%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20693429

18 June 2024

publication date

6 August 2010

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20693429%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

full work available at URL

http://www.bloodjournal.org/content/117/8/2358.full.pdf

Portable Document Format

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20693429

18 June 2024

http://www.bloodjournal.org/cgi/content/abstract/117/8/2358

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20693429

18 June 2024

http://ashpublications.org/blood/article-pdf/117/8/2358/1495456/zh800811002358.pdf

Portable Document Format

1 reference

10.1182/BLOOD-2010-03-273243

https://api.crossref.org/works/10.1182/BLOOD-2010-03-273243

18 June 2024

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20693429%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

117

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20693429%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20693429%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

2358-2365

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20693429%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Acute myeloid leukemia

2

1 reference

10.1182/BLOOD-2010-03-273243

https://api.crossref.org/works/10.1182/BLOOD-2010-03-273243

18 June 2024

Drug therapy for acute myeloid leukemia

3

1 reference

10.1182/BLOOD-2010-03-273243

https://api.crossref.org/works/10.1182/BLOOD-2010-03-273243

18 June 2024

A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study

6

1 reference

10.1182/BLOOD-2010-03-273243

https://api.crossref.org/works/10.1182/BLOOD-2010-03-273243

18 June 2024

Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study

9

1 reference

10.1182/BLOOD-2010-03-273243

https://api.crossref.org/works/10.1182/BLOOD-2010-03-273243

18 June 2024

A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan A

10

1 reference

10.1182/BLOOD-2010-03-273243

https://api.crossref.org/works/10.1182/BLOOD-2010-03-273243

18 June 2024

Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG AML97 study

11

1 reference

10.1182/BLOOD-2010-03-273243

https://api.crossref.org/works/10.1182/BLOOD-2010-03-273243

18 June 2024

Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML-87 Study of the Japan Adult Leukemia Study Group

12

1 reference

10.1182/BLOOD-2010-03-273243

https://api.crossref.org/works/10.1182/BLOOD-2010-03-273243

18 June 2024

Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group

13

1 reference

10.1182/BLOOD-2010-03-273243

https://api.crossref.org/works/10.1182/BLOOD-2010-03-273243

18 June 2024

Role of daunorubicin in the induction therapy for adult acute myeloid leukemia

15

1 reference

10.1182/BLOOD-2010-03-273243

https://api.crossref.org/works/10.1182/BLOOD-2010-03-273243

18 June 2024

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

17

1 reference

10.1182/BLOOD-2010-03-273243

https://api.crossref.org/works/10.1182/BLOOD-2010-03-273243

18 June 2024

"Proving the null hypothesis" in clinical trials

18

1 reference

10.1182/BLOOD-2010-03-273243

https://api.crossref.org/works/10.1182/BLOOD-2010-03-273243

18 June 2024

Nonparametric Estimation from Incomplete Observations

19

1 reference

10.1182/BLOOD-2010-03-273243

https://api.crossref.org/works/10.1182/BLOOD-2010-03-273243

18 June 2024

Asymptotically Efficient Rank Invariant Test Procedures

20

1 reference

10.1182/BLOOD-2010-03-273243

https://api.crossref.org/works/10.1182/BLOOD-2010-03-273243

18 June 2024

A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study

22

1 reference

10.1182/BLOOD-2010-03-273243

https://api.crossref.org/works/10.1182/BLOOD-2010-03-273243

18 June 2024

A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA.

24

1 reference

10.1182/BLOOD-2010-03-273243

https://api.crossref.org/works/10.1182/BLOOD-2010-03-273243

18 June 2024

High-dose daunorubicin in older patients with acute myeloid leukemia

28

1 reference

10.1182/BLOOD-2010-03-273243

https://api.crossref.org/works/10.1182/BLOOD-2010-03-273243

18 June 2024

Anthracycline dose intensification in acute myeloid leukemia

29

1 reference

10.1182/BLOOD-2010-03-273243

https://api.crossref.org/works/10.1182/BLOOD-2010-03-273243

18 June 2024

Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer

33

1 reference

10.1182/BLOOD-2010-03-273243

https://api.crossref.org/works/10.1182/BLOOD-2010-03-273243

18 June 2024

Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group

34

1 reference

10.1182/BLOOD-2010-03-273243

https://api.crossref.org/works/10.1182/BLOOD-2010-03-273243

18 June 2024

Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission

36

1 reference

10.1182/BLOOD-2010-03-273243

https://api.crossref.org/works/10.1182/BLOOD-2010-03-273243

18 June 2024

Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study

37

1 reference

10.1182/BLOOD-2010-03-273243

https://api.crossref.org/works/10.1182/BLOOD-2010-03-273243

18 June 2024

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

38

1 reference

10.1182/BLOOD-2010-03-273243

https://api.crossref.org/works/10.1182/BLOOD-2010-03-273243

18 June 2024

Identifiers

10.1182/BLOOD-2010-03-273243

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20693429%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20693429%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q84698071&oldid=2185042663"